Lennham Pharmaceuticals Announces Issuance Of US Patent Covering Deuterated Psilocybin Products

Lennham Pharmaceuticals, a clinical-stage start-up focused on the creative use of deuterium chemistry to improve the metabolic and pharmacological profile of existing compounds, today announced that the United States Patent & Trademark Office (USPTO) issued U.S. Patent No. 11,000,534 with an expiration date of December 2040. This patent broadly covers pharmaceutical compositions comprising deuterated forms of psilocybin. “Psilocybin has shown incredible promise in recent clinical studies as a potential treatment for major depressive disorder and other psychiatric diseases and disorders,” said Bradford C. Sippy, Founder and CEO of Lennham. “However, because psilocybin is a naturally occurring and extensively studied compound, it is unlikely that meaningful patent protection can be obtained on psilocybin or any products incorporating psilocybin. The issuance of this patent positions Lennham to have the most significant patent coverage for any psilocybin-based product in development. We intend to rapidly advance our differentiated product through the 505(b)(2) approval pathway by leveraging the existing known data on psilocybin.” The issued patent is entitled “Deuterated Derivatives of Psilocybin and Uses Thereof”. The issued claims are directed to pharmaceutical compositions comprising two forms of deuterium-enriched psilocybin.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!